QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 progyny-raises-fy2025-adj-eps-guidance-from-170-178-to-179-182-vs-062-est-raises-fy2025-sales-guidance-from-1235b-1270b-to-1263b-1278b-vs-1259b-est

Full Year 2025 Outlook:Revenue is now projected to be $1.263 billion to $1.278 billion, reflecting growth of 8.2% to 9.5%; excl...

 progyny-sees-q4-2025-adj-eps-037-040-vs-014-est-sees-sales-292700m-307700m-vs-302589m-est

Fourth Quarter of 2025 Outlook:Revenue is projected to be $292.7 million to $307.7 million, reflecting a change of (1.9)% to 3....

Core News & Articles

- Reuters

Core News & Articles

https://www.youtube.com/watch?v=xagrobF4q1k 

Core News & Articles

https://www.youtube.com/watch?v=xagrobF4q1k 

Core News & Articles

https://www.nytimes.com/2025/10/16/us/politics/trump-ivf-fertility.html

 jp-morgan-maintains-neutral-on-progyny-raises-price-target-to-25

JP Morgan analyst Anne Samuel maintains Progyny (NASDAQ:PGNY) with a Neutral and raises the price target from $23 to $25.

 canaccord-genuity-maintains-hold-on-progyny-raises-price-target-to-23

Canaccord Genuity analyst Richard Close maintains Progyny (NASDAQ:PGNY) with a Hold and raises the price target from $21 to ...

 cantor-fitzgerald-maintains-overweight-on-progyny-raises-price-target-to-28

Cantor Fitzgerald analyst Sarah James maintains Progyny (NASDAQ:PGNY) with a Overweight and raises the price target from $26...

 progyny-raises-fy2025-adj-eps-guidance-from-154-164-to-170-178-vs-054-est

Progyny (NASDAQ:PGNY) raises FY2025 Adj EPS guidance from $1.54-$1.64 to $1.70-$1.78 vs $0.54 analyst estimate..

 progyny-sees-q3-sales-290000m-305000m-vs-290721m-est

Progyny (NASDAQ:PGNY) sees Q3 sales of $290.000 million-$305.000 million vs $290.721 million analyst estimate.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION